CA2910877C - Expression process - Google Patents
Expression process Download PDFInfo
- Publication number
- CA2910877C CA2910877C CA2910877A CA2910877A CA2910877C CA 2910877 C CA2910877 C CA 2910877C CA 2910877 A CA2910877 A CA 2910877A CA 2910877 A CA2910877 A CA 2910877A CA 2910877 C CA2910877 C CA 2910877C
- Authority
- CA
- Canada
- Prior art keywords
- chinese hamster
- target polypeptide
- hamster ovary
- sequence
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 57
- 238000000034 method Methods 0.000 title claims abstract description 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 76
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 76
- 229920001184 polypeptide Polymers 0.000 claims abstract description 75
- 210000004027 cell Anatomy 0.000 claims abstract description 64
- 230000028327 secretion Effects 0.000 claims abstract description 58
- 108010067306 Fibronectins Proteins 0.000 claims abstract description 37
- 102000016359 Fibronectins Human genes 0.000 claims abstract description 37
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 29
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 29
- 239000002157 polynucleotide Substances 0.000 claims abstract description 29
- 239000013604 expression vector Substances 0.000 claims abstract description 25
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 33
- 239000013598 vector Substances 0.000 claims description 18
- 238000001890 transfection Methods 0.000 claims description 12
- 239000003550 marker Substances 0.000 claims description 11
- 241000699802 Cricetulus griseus Species 0.000 claims description 7
- 241001529936 Murinae Species 0.000 claims description 7
- 108010022394 Threonine synthase Proteins 0.000 claims description 7
- 108010006025 bovine growth hormone Proteins 0.000 claims description 7
- 102000004419 dihydrofolate reductase Human genes 0.000 claims description 7
- 108700039887 Essential Genes Proteins 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 5
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 claims description 4
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 claims description 4
- 101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 230000009466 transformation Effects 0.000 claims description 3
- 101001068154 Bos taurus Hemoglobin subunit beta Proteins 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 description 15
- 239000002609 medium Substances 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 101710137500 T7 RNA polymerase Proteins 0.000 description 4
- 238000013197 protein A assay Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000005571 anion exchange chromatography Methods 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102100039702 Alcohol dehydrogenase class-3 Human genes 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 101150082479 GAL gene Proteins 0.000 description 1
- 101150094690 GAL1 gene Proteins 0.000 description 1
- 101150038242 GAL10 gene Proteins 0.000 description 1
- 102100028501 Galanin peptides Human genes 0.000 description 1
- 102100024637 Galectin-10 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101100121078 Homo sapiens GAL gene Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 102000004867 Hydro-Lyases Human genes 0.000 description 1
- 108090001042 Hydro-Lyases Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 239000012515 MabSelect SuRe Substances 0.000 description 1
- 108010079246 OMPA outer membrane proteins Proteins 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
- 241000589776 Pseudomonas putida Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101000890996 Rattus norvegicus Fibronectin Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 101000890995 Xenopus laevis Fibronectin Proteins 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- -1 antibodies Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000006334 disulfide bridging Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 102000005396 glutamine synthetase Human genes 0.000 description 1
- 108020002326 glutamine synthetase Proteins 0.000 description 1
- 108010051015 glutathione-independent formaldehyde dehydrogenase Proteins 0.000 description 1
- LXJXRIRHZLFYRP-UHFFFAOYSA-N glyceraldehyde 3-phosphate Chemical compound O=CC(O)COP(O)(O)=O LXJXRIRHZLFYRP-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000001320 lysogenic effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 101150009573 phoA gene Proteins 0.000 description 1
- KCRZDTROFIOPBP-UHFFFAOYSA-N phosphono 2,3-dihydroxypropanoate Chemical compound OCC(O)C(=O)OP(O)(O)=O KCRZDTROFIOPBP-UHFFFAOYSA-N 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 239000012562 protein A resin Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201308017A GB201308017D0 (en) | 2013-05-03 | 2013-05-03 | Expression process |
| GB1308017.1 | 2013-05-03 | ||
| GB201320339A GB201320339D0 (en) | 2013-11-18 | 2013-11-18 | Expression Process |
| GB1320339.3 | 2013-11-18 | ||
| PCT/GB2014/000165 WO2014177826A1 (en) | 2013-05-03 | 2014-04-29 | Expression process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2910877A1 CA2910877A1 (en) | 2014-11-06 |
| CA2910877C true CA2910877C (en) | 2021-08-03 |
Family
ID=50639794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2910877A Active CA2910877C (en) | 2013-05-03 | 2014-04-29 | Expression process |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9873891B2 (enExample) |
| EP (1) | EP2992104B1 (enExample) |
| JP (1) | JP6545153B2 (enExample) |
| KR (1) | KR102180660B1 (enExample) |
| CN (2) | CN114395584B (enExample) |
| BR (1) | BR112015027373A2 (enExample) |
| CA (1) | CA2910877C (enExample) |
| DK (1) | DK2992104T3 (enExample) |
| ES (1) | ES2732907T3 (enExample) |
| RU (1) | RU2731717C2 (enExample) |
| SG (1) | SG11201508447TA (enExample) |
| WO (1) | WO2014177826A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3323826A1 (en) * | 2016-11-21 | 2018-05-23 | Danmarks Tekniske Universitet | Native chinese hamster ovary cell secretion signal peptides for production of recombinant polypeptides |
| JP7032438B2 (ja) | 2017-12-11 | 2022-03-08 | 富士フイルム株式会社 | 動物細胞、動物細胞の製造方法および目的タンパク質の製造方法 |
| EP3896168A4 (en) | 2018-12-11 | 2022-03-02 | FUJIFILM Corporation | ANIMAL CELLS, METHODS OF PRODUCTION OF ANIMAL CELLS AND METHODS OF PRODUCTION OF TARGET PROTEIN |
| CN109837277A (zh) * | 2019-03-01 | 2019-06-04 | 深圳生生凡非基因技术有限公司 | 一种cpgk嵌合型启动子、腺相关病毒载体及其应用 |
| WO2021107123A1 (ja) | 2019-11-29 | 2021-06-03 | 富士フイルム株式会社 | 細胞培養方法、抗体製造方法、有機酸除去方法、及び、抗体 |
| EP4276167A1 (en) | 2021-01-07 | 2023-11-15 | FUJIFILM Corporation | Cell selection method, device and device system |
| WO2022196710A1 (ja) | 2021-03-17 | 2022-09-22 | 富士フイルム株式会社 | 細胞培養方法、及び有用物質の製造方法 |
| CN112980852B (zh) * | 2021-05-18 | 2021-08-13 | 北京华芢生物技术有限公司 | 新型冠状病毒b.1.351南非突变株rbd的基因及其应用 |
| JP2024521784A (ja) | 2021-05-27 | 2024-06-04 | ヤンセン バイオテツク，インコーポレーテツド | 前立腺がんの治療のための組成物及び方法 |
| JPWO2023054556A1 (enExample) | 2021-09-30 | 2023-04-06 | ||
| JPWO2023112952A1 (enExample) | 2021-12-15 | 2023-06-22 | ||
| WO2023190300A1 (ja) | 2022-03-28 | 2023-10-05 | 富士フイルム株式会社 | 生産物の生産方法、及び生産物 |
| WO2023190829A1 (ja) | 2022-03-31 | 2023-10-05 | 富士フイルム株式会社 | 生産物の製造方法、及び生産物 |
| WO2023238949A1 (ja) | 2022-06-10 | 2023-12-14 | 富士フイルム株式会社 | 細胞の作出方法、ヘテロ多量体タンパク質の製造方法、バイスペシフィック抗体の製造方法、ベクターセット、哺乳動物細胞、ｃｈｏ細胞、及び細胞プールの作出方法 |
| JPWO2024071373A1 (enExample) | 2022-09-29 | 2024-04-04 | ||
| WO2025244971A1 (en) | 2024-05-20 | 2025-11-27 | Janssen Biotech, Inc. | Compositions and methods for the treatment of prostate cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003223766A1 (en) * | 2002-04-30 | 2003-11-17 | University Of North Carolina At Chapel Hill | Secretion signal vectors |
| US7186699B2 (en) * | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
| US8029783B2 (en) * | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
| EP1739179A1 (en) * | 2005-06-30 | 2007-01-03 | Octapharma AG | Serum-free stable transfection and production of recombinant human proteins in human cell lines |
| GB0602173D0 (en) * | 2006-02-03 | 2006-03-15 | Avecia Ltd | Expression system |
| CN101646775B (zh) * | 2006-12-28 | 2016-08-24 | 森托科尔奥索生物科技公司 | 用于产生脱唾液酸化免疫球蛋白的方法和载体 |
| KR101618767B1 (ko) * | 2008-09-02 | 2016-05-09 | 한국생명공학연구원 | 외래단백질을 고효율로 생산하는 리더서열 |
| CN102272160A (zh) * | 2008-12-31 | 2011-12-07 | 印度血清及疫苗有限公司 | 抗rhd单克隆抗体 |
| PE20160653A1 (es) | 2009-03-05 | 2016-07-24 | Abbvie Inc | Proteinas de union a il-17 |
| GB0905331D0 (en) * | 2009-03-27 | 2009-05-13 | Avecia Biolog Ltd | Expression process |
| KR101420274B1 (ko) * | 2011-06-13 | 2014-07-21 | 주식회사 종근당 | Ｃｓｐ－ｂ ５＇ｓａｒ 인자를 포함하는 동물세포 발현 벡터 및 이를 이용한 재조합 단백질의 제조방법 |
-
2014
- 2014-04-29 ES ES14721474T patent/ES2732907T3/es active Active
- 2014-04-29 WO PCT/GB2014/000165 patent/WO2014177826A1/en not_active Ceased
- 2014-04-29 BR BR112015027373A patent/BR112015027373A2/pt not_active Application Discontinuation
- 2014-04-29 JP JP2016511126A patent/JP6545153B2/ja active Active
- 2014-04-29 EP EP14721474.6A patent/EP2992104B1/en active Active
- 2014-04-29 KR KR1020157032562A patent/KR102180660B1/ko active Active
- 2014-04-29 US US14/787,669 patent/US9873891B2/en active Active
- 2014-04-29 DK DK14721474.6T patent/DK2992104T3/da active
- 2014-04-29 CN CN202111508425.XA patent/CN114395584B/zh active Active
- 2014-04-29 CA CA2910877A patent/CA2910877C/en active Active
- 2014-04-29 CN CN201480024993.4A patent/CN105392889A/zh active Pending
- 2014-04-29 RU RU2015151626A patent/RU2731717C2/ru active
- 2014-04-29 SG SG11201508447TA patent/SG11201508447TA/en unknown
-
2017
- 2017-12-12 US US15/838,868 patent/US11306323B2/en active Active
-
2022
- 2022-03-15 US US17/694,760 patent/US20220213500A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN105392889A (zh) | 2016-03-09 |
| US11306323B2 (en) | 2022-04-19 |
| SG11201508447TA (en) | 2015-11-27 |
| CN114395584B (zh) | 2025-01-28 |
| US20220213500A1 (en) | 2022-07-07 |
| CN114395584A (zh) | 2022-04-26 |
| RU2015151626A3 (enExample) | 2018-03-20 |
| RU2731717C2 (ru) | 2020-09-08 |
| JP6545153B2 (ja) | 2019-07-17 |
| KR102180660B1 (ko) | 2020-11-19 |
| EP2992104A1 (en) | 2016-03-09 |
| ES2732907T3 (es) | 2019-11-26 |
| WO2014177826A1 (en) | 2014-11-06 |
| KR20160003705A (ko) | 2016-01-11 |
| US20180127777A1 (en) | 2018-05-10 |
| BR112015027373A2 (pt) | 2017-08-29 |
| EP2992104B1 (en) | 2019-04-17 |
| RU2015151626A (ru) | 2017-06-08 |
| US9873891B2 (en) | 2018-01-23 |
| JP2016517691A (ja) | 2016-06-20 |
| DK2992104T3 (da) | 2019-07-15 |
| US20160076051A1 (en) | 2016-03-17 |
| CA2910877A1 (en) | 2014-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220213500A1 (en) | Expression Process | |
| US10611831B2 (en) | Production cell line enhancers | |
| CN112912392B (zh) | 利用重组酶介导的盒式交换的多特异性抗体筛选方法 | |
| CA3141039A1 (en) | Mammalian cell lines with sirt-1 gene knockout | |
| JP7410983B2 (ja) | Ｃｒｅ ｍＲＮＡを使用した標的指向性組込みによるタンパク質発現細胞の作製のための方法 | |
| US9845475B2 (en) | Expression vector | |
| JP7446342B2 (ja) | 所定の構成の複数の発現カセットの標的化組込みによって三価の抗体を発現する細胞を生成するための方法 | |
| JP7572977B2 (ja) | 所定の構成の複数の発現カセットの標的化組込みによって多価の多重特異性抗体発現細胞を作製するための方法 | |
| JP2025510718A (ja) | 哺乳動物細胞における選択マーカーとしての細菌グルタミン合成酵素 | |
| EP2922962B1 (en) | Optimized expression cassette for expressing a polypeptide with high yield | |
| US20250282894A1 (en) | Expression technology for antibody constructs | |
| WO2015033086A1 (en) | Dna construct | |
| US20250361524A1 (en) | Method for producing cells, method for producing heteromultimeric protein, method for producing bispecific antibody, and method for producing vector set, mammalian cells, CHO cells, and cell pool | |
| WO2008035463A1 (en) | Antibody class switching method | |
| CN120322561A (zh) | 新型转座酶系统 | |
| CN104558180A (zh) | 靶向t淋巴细胞的人源单链抗体 | |
| HK40007802A (en) | Production of seleno-biologics in genomically recoded organisms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190429 |